

Resolution

of the Federal Joint Committee on an Amendment of the
Pharmaceuticals Directive:

Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a SGB V and
Annex XIIa – Naming of Medicinal Products with New
Active Ingredients according to Section 35a, paragraph 3,
sentence 4

SGB V:

Vigabatrin (repeal of the resolutions of 19 December 2019
and repeal of the naming)

of 6 February 2025

At its session on 6 February 2025, the Federal Joint Committee (G-BA) resolved to amend the
Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009
(Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the
resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. Annex XII is amended as follows:

1. The findings on the benefit assessment of the active ingredient vigabatrin in the
therapeutic indication according to the marketing authorisation of 20 September
2018 for treatment in combination with other anti-epileptic medicines for patients
with resistant partial epilepsy (focal onset seizures) with or without secondary
generalisation, that is where all other appropriate medicinal product combinations
have proved inadequate or have not been tolerated, in Annex XII of the
Pharmaceuticals Directive in the version of the resolution of 19 December 2019
(BAnz AT 17.01.2020 B2), last amended on 5 October 2023 (BAnz AT 22.01.2024
B2), are deleted.
2. The findings on the benefit assessment of the active ingredient vigabatrin in the
therapeutic indication according to the marketing authorisation of 20 September
2018 for treatment in monotherapy of infantile spasms (West's syndrome) in
children from 1 month to less than 7 years of age, in Annex XII of the
Pharmaceuticals Directive in the version of the resolution of 19 December 2019
(BAnz AT 20.01.2020 B3), are deleted.

II. Annex XIIa is amended as follows:

1. The information on the active ingredient vigabatrin of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 19 December 2019) in the version of the resolution of 5 October 2023 (BANz AT 22.01.2024 B2) is deleted.
2. The information on the active ingredient brivaracetam of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 17 January 2019) in the version of the resolution of 5 October 2023 (BANz AT 22.01.2024 B4) is amended as follows:

The information "Vigabatrin (Kigabeq)" is deleted after the heading "Naming of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V (active ingredients and invented names²)".

3. The information on the active ingredient brivaracetam of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 1 September 2022) in the version of the resolution of 5 October 2023 (BANz AT 22.01.2024 B2) is amended as follows:

The information "Vigabatrin (Kigabeq)" is deleted after the heading "Naming of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V (active ingredients and invented names²)".

4. The information on the active ingredient cannabidiol of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 15 April 2021 and resolution according to Section 35a paragraph 3 SGB V of 16 May 2024) in the version of the resolution of 16 May 2024 (BANz AT 02.07.2024 B3) is amended as follows:

The information "Vigabatrin (Kigabeq)" is deleted after the heading "Naming of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V (active ingredients and invented names²)".

5. The information on the active ingredient cannabidiol of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 15 April 2021 and resolution according to Section 35a paragraph 3 SGB V of 16 May 2024) in the version of the resolution of 16 May 2024 (BANz AT 02.07.2024 B5) is amended as follows:

The information "Vigabatrin (Kigabeq)" is deleted below the heading "Naming of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V (active ingredients and invented names²)".

6. The information on the active ingredient cannabidiol of the assessed medicinal product (resolution according to Section 35a paragraph 3 SGB V of 4 November 2021 and resolution according to Section 35a paragraph 3 SGB V of 16 May 2024) in the version of the resolution of 16 May 2024 (BANz AT 02.07.2024 B4) is amended as follows:

The information "Vigabatrin (Kigabeq)" is deleted below the heading "Naming of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V (active ingredients and invented names²)".

- III. The resolution will enter into force on the day of its publication on the website of the G-BA on 6 February 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 6 February 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken

Resolution has been modified by another benefit assessment procedure.
Please note the current version of the Pharmaceuticals Directive/Annex XII.